Blogs

30 Apr Ivosidenib and Azacitidine combination shows significant clinical benefit in newly diagnosed IDH1-mutated AML

n patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive induction therapy, Ivosidenib/Azacitidine combination showed significantly longer EFS compared to Azacitidine at a median follow-up of 12.4 months. The median OS was 24.0 months with Ivosidenib/Azacitidine and 7.9 months with Azacitidine. Febrile neutropenia and infections were less frequent with Ivosidenib/Azacitidine than Azacitidine.
(Ref: Montesinos P et al. N Engl J Med. April 21,2022)

#oncologyresearch #drugdevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6926072382784704512

23 Apr Fuzuloparib as Maintenance Therapy is Effective Regardless of BRCA 1/2 Mutation

In patients with platinum-sensitive, recurrent ovarian cancer previously treated with at least two platinum-based regimens, Fuzuloparib as a maintenance therapy showed a significantly improved progression-free survival compared with placebo, regardless of germline BRCA 1/2 mutation. (Ref: Li N et al. J Clin Oncol. April 11, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6923581090574000128

16 Apr Ibrutinib Plus Rituximab Elicits High Responses in Indolent Mantle Cell Lymphoma

Indolent MCL patients treated with frontline ibrutinib plus rituximab showed an overall response of 84% after 12 cycles of treatment, with 80% of patients experiencing a CR. Undetectable MRD in the peripheral blood was achieved in 87% of patients. The estimated PFS at 36 months was 93%. At 2 years, 69% of patients could discontinue ibrutinib because of undetectable MRD. (Ref: Giné E et al. J Clin Oncol. 2022)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6921011455219646464

01 Apr Trastuzumab Deruxtecan Superior to Trastuzumab Emtansine in Metastatic HER2-positive Breast Cancer

In patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower with trastuzumab deruxtecan than trastuzumab emtansine [Hazard ratio – 0.28 (p<0.001)]. The corresponding overall survival rate was 94.1% and 85.9% after 12 months, and the overall response was 79.7% and 34.2%. (Ref: Cortés J, et al. N Engl J Med March 24, 2022).
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6915618089447387136

26 Mar Rucaparib significantly prolongs PFS compared with chemotherapy in women with BRCA-mutated advanced, relapsed ovarian cancer, who received 3 or more lines of prior therapies

In patients with relapsed, BRCA1-mutated or BRCA2-mutated ovarian cancer, who received 2 or more lines of prior therapies, Rucaparib showed significantly longer median progression-free survival of 7.4 months compared to 5.7 months with chemotherapy (platinum-based and non-platinum-based chemotherapy). # ARIEL4 study. (Ref: Kristeleit R et al. The lancet Oncology March 14, 2022)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6913402413664104448

19 Mar Ribociclib Plus Letrozole Extends Survival in Patients with Metastatic Breast Cancer

Ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole. Median overall survival was 63.9 months (95% CI, 52.4 to 71.0) with ribociclib plus letrozole and 51.4 months (95% CI, 47.2 to 59.7) with placebo plus letrozole (HR for death, 0.76; 95% CI, 0.63 to 0.93; P=0.008).

Front line therapy with the combo improved median overall survival by 1 year compared to letrozole alone.
(Ref: Hortobagyi et al.NEJM March 10, 2022.)

https://www.linkedin.com/feed/update/urn:li:activity:6910855914283540480

11 Mar Mechanisms of resistance to noncovalent Bruton Tyrosine Kinase inhibitors is delineated

The mechanisms of resistance to noncovalent (reversible) BTK inhibitors was not fully known. Genomic analyses of pre and post-treatment samples from patients with CLL treated with the non-covalent BTK inhibitor pirtobrutinib showed that resistance to noncovalent BTK inhibitors arose through on-target BTK mutations and downstream PLCγ2 mutations. This data suggests new mechanisms of genomic escape from established covalent and novel noncovalent BTK inhibitors. (Ref: Wang E et al.NEJM, 2022)

https://www.linkedin.com/feed/update/urn:li:activity:6907962121779597312

04 Jan Trastuzumab Deruxtecan Superior to Trastuzumab Emtansine in Metastatic HER2-positive Breast Cancer

In patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower with trastuzumab deruxtecan than trastuzumab emtansine [Hazard ratio – 0.28 (p<0.001)]. The corresponding overall survival rate was 94.1% and 85.9% after 12 months, and the overall response was 79.7% and 34.2%. (Ref: Cortés J, et al. N Engl J Med March 24, 2022).

#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6915618089447387136

11 Dec Vaccine Booster Dose and Mortality Due to Covid-19

Participants who received a booster at least 5 months after a second dose of Covid-19 vaccine had 90% lower mortality due to Covid-19 than participants who did not receive a booster. The adjusted hazard ratio for death due to Covid-19 in the booster group, as compared with the non-booster group, was 0.10 (95% confidence interval, 0.07 to 0.14; P<0.001). (Ref: Arbel R et al NEJM Dec 8, 2021)
#covid #research

https://www.linkedin.com/feed/update/urn:li:activity:6875388315416199168

20 Nov Next Generation Therapeutics for the Treatment of Myelofibrosis

Multiple non-JAK inhibitor-based therapies are being explored in pre-clinical and clinical settings for the treatment of myelofibrosis, targeting outside of the JAK-STAT pathway. (Ref: Tremblay D et al. Cells. 2021)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6867852221321658368